MODULATION OF FUNCTIONAL MACROPHAGE ACTIVITY BY HLDF6 PEPTIDE UPON ADDING OPIATE RECEPTOR AGONISTS

Abstract.The effect of a hexamer fragment of the peptide differentiation factor of the HL–60 cell line, HLDF6, on functional activity of C57Bl/6 mouse macrophages upon adding selective agonists of μ–, δ– and κ–type opiate receptors (DAGO, DADLE and Dynorphin (1–13) has been studied in the cell culture. It has been shown that opiate agonists were capable of enhancing adhesive properties and functional activity of macrophages during their direct interaction with cells. The intensity of stimulation depended on the type of the agonist and, respectively, the type of the opiate receptor. HLDF6 peptide enhanced macrophage activity after addition to the culture medium both at the initial cultivation stage and at the moment of phagosytosis induction. The data concerning the combined administration of HLDF6 and opiate agonists suggest the interaction between the peptide and the endogenous opiate system. (Med. Immunol., 2005, vol.7, № 1, pp 77584

ANTIBODIES TO LEUKEMIA DIFFERENTIATION FACTOR (HLDF) IN PATIENTS WITH GASTROINTESTINAL CANCER

Antibodies to leukemia differentiation factor (HLDF) in patients with gastrointestinal cancer Abstract. Patients with gastric cancer exhibit higher levels of IgG4-antibodies to human leukemia differentiation factor (HLDF), as compared with healthy individuals, whereas, in patients with colorectal cancer, one may detect high levels of IgA anti-HDLF antibodies, along with lower levels of IgG1 class antibodies against HLDF than in control group. Among patients with gastrointestinal cancer, a positive correlation is revealed between contents of highly differentiated cells in the tumor, and IgM antibodies to HDLF. Meanwhile, a reverse relationship is noted between low differentiation of tumor cells and levels of IgG2 antibodies to HDLF in gastric cancer patients, or IgG3 antibodies to HDLF in patients with colorectal cancer